Related news from
Wed, 09 Sep 2026 12:19:08 +0000	Is Cencora Stock Underperforming the Dow? Despite lagging behind the Dow over the past 12 months, Cencora continues to receive a highly bullish outlook from Wall Street analysts.
Fri, 04 Sep 2026 15:30:28 +0000	Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue? Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 04 Sep 2026 13:37:00 +0000	Cencora Launches Cell and Gene Therapy Enablement for Health Systems COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Fri, 04 Sep 2026 07:07:34 +0000	Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings? Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 2026 guidance come after a strong run, with the share price up 22.6% over 90 days and a 1 year total shareholder return of 16.1%, building on a 5 year total shareholder return of 186.8%. Capitalize on Cencora's earnings momentum by scanning a hand picked group...
Thu, 03 Sep 2026 22:40:35 +0000	What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also raising its fiscal 2026 adjusted earnings outlook following stronger-than-expected third-quarter results. The combination of expanded capabilities in cell and gene therapies and faster profit growth across its healthcare solutions segments highlights how Cencora is deepening its role in complex,...
Thu, 03 Sep 2026 19:22:00 +0000	Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Thu, 03 Sep 2026 13:11:39 +0000	Artisan Sold Cencora (COR) as Earnings Momentum Slowed Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]
Mon, 14 Sep 2026 13:00:00 +0000	Coultreon Biopharma Appoints Nate Massari as Chief Business Officer Nate Massari’s business development and commercialization expertise in Immunology & Inflammation (I&I), particularly in ulcerative colitis and Crohn’s disease, will support the advancement of Coultreon's first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. September 14, 2026. Coultreon Biopharma, a clinical-stage biotechnology company developing best-in-class immunology therapies, today announced the appointment of Nate Massari as Chief Business Officer. Nate brings more than 25 years of expe
Fri, 04 Sep 2026 18:50:01 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Mon, 14 Sep 2026 15:00:55 +0000	AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
Mon, 14 Sep 2026 11:03:45 +0000	Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.
Fri, 11 Sep 2026 18:21:00 +0000	CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue? Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
Fri, 11 Sep 2026 15:49:37 +0000	Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.
Fri, 11 Sep 2026 15:29:27 +0000	Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
Thu, 10 Sep 2026 17:46:13 +0000	AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Thu, 10 Sep 2026 17:45:04 +0000	2 S&P 500 Stocks with Exciting Potential and 1 We Question The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Thu, 10 Sep 2026 16:21:24 +0000	Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
Tue, 08 Sep 2026 20:23:18 +0000	Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.
Fri, 04 Sep 2026 19:39:00 +0000	Here's Why You Should Retain Cencora Stock in Your Portfolio for Now Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Thu, 03 Sep 2026 21:52:55 +0000	Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore” On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!